Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …

Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not
been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Lung cancer is the leading cause of cancer mortality. It is classified into different histologic
subtypes, including adenocarcinoma, squamous carcinoma, and large cell carcinoma …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–
small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors …

Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …